Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Steindl-Munda, P; Ferenci, P; Brunner, H; Nachbaur, K; Datz, C; Gschwantler, M; Hofer, H; Stauber, R; Hackl, F; Jessner, W; Rosenbeiger, M; Gangl, A; Vogel, W; Austrian Hepatitis Study Group.
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Liver Int. 2003; 23(4):269-275
Doi: 10.1034%2Fj.1600-0676.2003.00838.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hofer Herwig
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND/AIMS: Initial high-dose interferon-alpha induction therapy in combination with ribavirin improves sustained response rates in treatment-naïve patients. This prospective, randomized, controlled study tested whether non-responders or relapsers to interferon monotherapy also benefit from induction therapy. METHODS: Patients with chronic hepatitis C who had not responded to (n=75) or relapsed (n=80) after previous interferon therapy were randomized to receive three different interferon doses during the first 14 weeks of therapy (A: 10 MU IntronA/day for 2 weeks, followed by 10 MU/2 days for 12 weeks; B:5 MU/d for 14 weeks; C: 5 MU/2 days for 14 weeks) followed in all by 5 MU/2 days for 24 weeks. All patients received 1-1.2 g ribavirin/day throughout the whole study. RESULTS: The rates of viral clearance at any time on treatment were similar in all groups. Sustained response rates were also not different among the groups in interferon nonresponders (A 32%, B 29%, C 31%) and relapsers (A 64%, B 68%, C 71%), respectively, as well as in patients with different genotypes. As expected, sustained response rates were higher in patients with genotype non-1 than in those with genotype 1. CONCLUSION: High-dose induction therapy does not improve the outcome of interferon/ribavirin therapy in interferon nonresponders or relapsers.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Adult -
- Aged -
- Antiviral Agents - administration and dosage
- Dose-Response Relationship, Drug - administration and dosage
- Drug Resistance, Viral - drug effects
- Drug Therapy, Combination - drug effects
- Female - drug effects
- Hepacivirus - genetics
- Hepatitis C, Chronic - blood
- Humans - blood
- Injections, Subcutaneous - blood
- Interferon Alfa-2b - administration and dosage
- Male - administration and dosage
- Middle Aged - administration and dosage
- Polymerase Chain Reaction - administration and dosage
- Prospective Studies - administration and dosage
- RNA, Viral - blood
- Recurrence - blood
- Retreatment - blood
- Ribavirin - administration and dosage
- Treatment Outcome - administration and dosage
- Viral Load - administration and dosage
- Find related publications in this database (Keywords)
- hepatitis C
- nonresponders
- relapsers
- high-dose induction therapy